Literature DB >> 15456533

A novel PPAR alpha/gamma dual agonist inhibits cell growth and induces apoptosis in human glioblastoma T98G cells.

Da-Chuan Liu1, Chuan-Bing Zang, Hong-Yu Liu, Kurt Possinger, Shao-Guang Fan, Elena Elstner.   

Abstract

AIM: To examine the effect of a novel peroxisome proliferator-activated receptor (PPAR) alpha/gamma dual agonist TZD18 on cell proliferation and apoptosis in human glioblastoma T98G cells and its possible mechanism.
METHODS: RT-PCR, MTT, TUNEL, Flow cytometry, and Western blot analysis were employed.
RESULTS: TZD18 inhibited the growth of T98G cells in a concentration-dependent manner, which was associated with a G1 to S cell cycle arrest. Besides, significant apoptosis was induced after treatment with a non-toxic dose of TZD18. During the process, the expression of Bcl-2 protein was down-regulated, while that of Bax and p27kip proteins was up-regulated, and the activity of caspase-3 was elevated. However, this effect appeared to be PPARalpha and PPARgamma independent since their antagonists could not reverse this effect.
CONCLUSIONS: TZD18, a novel PPARalpha/gamma dual agonist, inhibited cell growth and induce apoptosis in human glioblastoma T98G cells in vitro, indicating a therapeutic potential for TZD18 in the treatment of glioblastoma. Copyright 2004 Acta Pharmacologica Sinica

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15456533

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  21 in total

1.  Probucol suppresses human glioma cell proliferation in vitro via ROS production and LKB1-AMPK activation.

Authors:  Yong-sheng Jiang; Jing-an Lei; Fang Feng; Qi-ming Liang; Fu-rong Wang
Journal:  Acta Pharmacol Sin       Date:  2014-11-17       Impact factor: 6.150

2.  Expression of peroxisome proliferator activated receptor-gamma (PPAR-γ) in human non-small cell lung carcinoma: correlation with clinicopathological parameters, proliferation and apoptosis related molecules and patients' survival.

Authors:  Costantinos Giaginis; Ekaterini Politi; Paraskevi Alexandrou; John Sfiniadakis; Gregory Kouraklis; Stamatios Theocharis
Journal:  Pathol Oncol Res       Date:  2012-03-18       Impact factor: 3.201

3.  PPARα inhibition modulates multiple reprogrammed metabolic pathways in kidney cancer and attenuates tumor growth.

Authors:  Omran Abu Aboud; Dallas Donohoe; Scott Bultman; Mark Fitch; Tim Riiff; Marc Hellerstein; Robert H Weiss
Journal:  Am J Physiol Cell Physiol       Date:  2015-03-25       Impact factor: 4.249

4.  A peroxisome proliferator-activated receptor ligand MCC-555 imparts anti-proliferative response in pancreatic cancer cells by PPARgamma-independent up-regulation of KLF4.

Authors:  Kyung-Won Min; Xiaobo Zhang; Temjenmongla Imchen; Seung Joon Baek
Journal:  Toxicol Appl Pharmacol       Date:  2012-06-30       Impact factor: 4.219

5.  Comparative effects of fatty acids on endothelial inflammatory gene expression.

Authors:  Danielle I Shaw; Wendy L Hall; Natasha R Jeffs; Christine M Williams
Journal:  Eur J Nutr       Date:  2007-08-21       Impact factor: 5.614

Review 6.  Opposite Interplay Between the Canonical WNT/β-Catenin Pathway and PPAR Gamma: A Potential Therapeutic Target in Gliomas.

Authors:  Alexandre Vallée; Yves Lecarpentier; Rémy Guillevin; Jean-Noël Vallée
Journal:  Neurosci Bull       Date:  2018-03-26       Impact factor: 5.203

7.  Peroxisome Proliferator-Activated Receptors (PPARs) as Potential Inducers of Antineoplastic Effects in CNS Tumors.

Authors:  Lars Tatenhorst; Eric Hahnen; Michael T Heneka
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

8.  Current understanding of the role of PPARγ in gastrointestinal cancers.

Authors:  Bing Zou; Liang Qiao; Benjamin C Y Wong
Journal:  PPAR Res       Date:  2009-10-26       Impact factor: 4.964

9.  PTB-associated splicing factor (PSF) is a PPARγ-binding protein and growth regulator of colon cancer cells.

Authors:  Tamotsu Tsukahara; Hisao Haniu; Yoshikazu Matsuda
Journal:  PLoS One       Date:  2013-03-13       Impact factor: 3.240

10.  PPARgamma agonists inhibit growth and expansion of CD133+ brain tumour stem cells.

Authors:  W Chearwae; J J Bright
Journal:  Br J Cancer       Date:  2008-11-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.